Scott A. Byrd

Mallinckrodt Hospital Products, Inc. operates as a biopharmaceutical company, which develops and commercializes proprietary product candidates used in the hospital setting. The firm offers OFIRMEV (acetaminophen injection), a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The company was founded by Theodore R. Schroeder, David A. Socks, and Cam L. Garner on May 26, 2004 and is headquartered in Hazelwood, MO.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Acacia Pharma Group Plc is a holding company, which engages in the development and commercialization of pharmaceutical product. It focuses on the new nausea and vomiting treatments for surgical and cancer patients. The company was founded by Julian Clive Gilbert, Robert William Gristwood, and Andrew Muncey in 2007 and is headquartered in Duxford, the United Kingdom.

Part of Eagle Pharmaceuticals, Inc., Acacia Pharma, Inc. distributes pharmaceutical products. The private company is based in Dover, DE.

Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA.

Part of Outpost Medicine, Inc., Outpost Medicine Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The private company is based in London, UK. The company was founded in 2016. Scott A. Byrd has been the CEO of the company since 2017.

AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.

Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd.